- Business
- Mediplantex National Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical manufacturing and commercial trading enterprise specializing in modern synthetic pharmaceuticals, traditional herbal remedies, active pharmaceutical ingredients, and dietary supplements. Founded in 1958 and headquartered in Hanoi, Vietnam, the company operates advanced production facilities certified under World Health Organization Good Manufacturing Practice, Good Laboratory Practice, and Good Storage Practice standards. The company's core product portfolio and service offerings comprise: cerebral and cardiovascular circulation therapies, including the flagship Cerecaps brand; hepatoprotective and metabolic drugs, including Silymax and Silymax Complex; central nervous system and neurological medicines, such as Dicenin; immune enhancement formulations, including Mediphylamin; nutritional and vitamin supplements, such as Bequantene; broad-spectrum antibiotics, analgesics, antipyretics, and anti-inflammatory medications; respiratory and gastrointestinal therapeutic agents, including botanical syrups and digestive aids; processed traditional medicinal herbs and standardized plant extracts; natural essential oils, including star anise, cinnamon, peppermint, and lemongrass distillates; and comprehensive commercial import-export services covering pharmaceutical raw materials, fine chemicals, medical equipment, and pharmaceutical packaging materials. Mediplantex serves both institutional healthcare providers through hospital tender channels and consumers through nationwide retail pharmacy distribution networks coordinated via branches in Hanoi, Ho Chi Minh City, and Bac Giang, while maintaining export operations to international markets across Asia and Europe, including Laos, Cambodia, Japan, India, Russia, the United Kingdom, and France. In recent corporate developments, the company is executing a strategic investment program valued at approximately 780 billion Vietnamese dong to construct a high-technology pharmaceutical manufacturing and research center at the Hoa Lac High-Tech Park in Hanoi, designed to comply with European Union Good Manufacturing Practice standards. This facility integrates advanced pharmaceutical processing technologies, including supercritical fluid carbon dioxide extraction for herbal actives, polymer liposome manufacturing, and nanomedicine delivery systems. Furthermore, Mediplantex has intensified strategic initiatives to expand its institutional healthcare supply agreements, broadened international cooperation under regional pharmaceutical initiatives such as the K-MEDI Silk Road project, and modernized its manufacturing lines to support higher-value domestic production and international regulatory approvals.